Trial · NCT01373164
Participant flow20
How many started, completed or left each group, period by period.
1 to 20 of 20
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Phase 1b: 80 mg (Milligrams) Galunisertib + Gemcitabine | 5 | |
| Overall Study | STARTED | Phase 1b: 160 mg Galunisertib + Gemcitabine | 4 | |
| Overall Study | STARTED | Phase 1b: 300 mg Galunisertib + Gemcitabine | 5 | |
| Overall Study | STARTED | Phase 2: 300 mg Galunisertib + Gemcitabine | 104 | |
| Overall Study | STARTED | Phase 2: Placebo + Gemcitabine | 52 | |
| Overall Study | Received at Least One Dose | Phase 1b: 80 mg (Milligrams) Galunisertib + Gemcitabine | 5 | |
| Overall Study | Received at Least One Dose | Phase 1b: 160 mg Galunisertib + Gemcitabine | 4 | |
| Overall Study | Received at Least One Dose | Phase 1b: 300 mg Galunisertib + Gemcitabine | 5 | |
| Overall Study | Received at Least One Dose | Phase 2: 300 mg Galunisertib + Gemcitabine | 103 | |
| Overall Study | Received at Least One Dose | Phase 2: Placebo + Gemcitabine | 52 | |
| Overall Study | COMPLETED | Phase 1b: 80 mg (Milligrams) Galunisertib + Gemcitabine | 5 | |
| Overall Study | COMPLETED | Phase 1b: 160 mg Galunisertib + Gemcitabine | 3 | |
| Overall Study | COMPLETED | Phase 1b: 300 mg Galunisertib + Gemcitabine | 4 | |
| Overall Study | COMPLETED | Phase 2: 300 mg Galunisertib + Gemcitabine | 92 | |
| Overall Study | COMPLETED | Phase 2: Placebo + Gemcitabine | 50 | |
| Overall Study | NOT COMPLETED | Phase 1b: 80 mg (Milligrams) Galunisertib + Gemcitabine | 0 | |
| Overall Study | NOT COMPLETED | Phase 1b: 160 mg Galunisertib + Gemcitabine | 1 | |
| Overall Study | NOT COMPLETED | Phase 1b: 300 mg Galunisertib + Gemcitabine | 1 | |
| Overall Study | NOT COMPLETED | Phase 2: 300 mg Galunisertib + Gemcitabine | 12 | |
| Overall Study | NOT COMPLETED | Phase 2: Placebo + Gemcitabine | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01373164/flow